Phosphorus,calcium, magnesium, 25-hydroxy vitamin D, and parathyroid hormone levels before and after FCM infusion were obtained from the medical records.Hypophosphatemia was defined as serum phosphorus level of
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Aim: The aim of this study was to evaluate the incidence of hypophosphatemia after ferric carboxymaltose (FCM) infusion and the factors affectinghypophosphatemia.Materials and Methods: Ninety-two patients who received FCM treatment for iron deficiency anemia (IDA) were included in the study.
📊
Key Findings & Data:Aim: The aim of this study was to evaluate the incidence of hypophosphatemia after ferric carboxymaltose (FCM) infusion and the factors affectinghypophosphatemia.Materials and Methods: Ninety-two patients who received FCM treatment for iron deficiency anemia (IDA) were included in the study.
💡
Conclusion & Impact:Phosphorus,calcium, magnesium, 25-hydroxy vitamin D, and parathyroid hormone levels before and after FCM infusion were obtained from the medical records.Hypophosphatemia was defined as serum phosphorus level of
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
Aim: The aim of this study was to evaluate the incidence of hypophosphatemia after ferric carboxymaltose (FCM) infusion and the factors affectinghypophosphatemia.Materials and Methods: Ninety-two patients who received FCM treatment for iron deficiency anemia (IDA) were included in the study. Phosphorus,calcium, magnesium, 25-hydroxy vitamin D, and parathyroid hormone levels before and after FCM infusion were obtained from the medical records.Hypophosphatemia was defined as serum phosphorus level of
Özet
Amaç: Demir karboksimaltoz (DKM) infüzyonu sonrası hipofosfatemi sıklığını ve hipofosfatemiye etki eden faktörleri değerlendirmek amaçlanmıştır. Gereç ve Yöntem: Demir eksikliği anemisi (DEA) nedeniyle DKM tedavisi alan 92 hasta çalışmaya alındı. DKM öncesi ve sonrası fosfor, kalsiyum, magnezyum, 25-hidroksi vitamin D, parathormon seviyeleri dosya bilgilerinden kaydedildi. Hipofosfatemi serum fosfor düzeyinin
🔖
Cite This Article
DEMİRSOY, E. T. (2022). Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience. Namık Kemal Tıp Dergisi, Cilt: 9 - Sayı: 2, 201–206. https://ajindex.com/articles/584052
World Health Organization. Iron Deficiency Anaemia Assessment, Prevention, and Control. A guide for programme managers. Switzerland: World Health Organization; 2001
World Health Organization. The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015
Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, Haya-Palazuelos J, Ciria-Recasens M, Manasanch J, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013;29:291-303
Gereklioglu C, Asma S, Korur A, Erdogan F, Kut A. Medication adherence to oral iron therapy in patients with iron deficiency anemia. Pak J Med Sci. 2016;32:604-7
Qunibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung. 2010;60:399-412
Emrich IE, Lizzi F, Siegel JD, Seiler-Mussler S, Ukena C, Kaddu-Mulindwa D, et al. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study. BMC Med. 2020;18:178
Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron- Deficiency Anemia: Two Randomized Clinical Trials. JAMA. 2020;323:432- 43
Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W. Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight. 2018;3:e124486
World Health Organization, Worldwide Prevalance of Anemia 1993- 2005. WHO Global Database on Anaemia. Switzerland: World Health Organization; 2008
Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. Am Fam Physician. 2013;87:98-104
World Health Organization, International statistical classification of diseases and related health problems. - 10th revision, World Health Organization Geneva, Switzerland: 2016
Cançado RD, Muñoz M. Intravenous iron therapy: how far have we come? Rev Bras Hematol Hemoter. 2011;33:461-9
Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol. 2014;5:48-60
Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, et al. Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review. Ther Clin Risk Manag. 2020;16:245-59
Hardy S, Vandemergel X. Intravenous iron administration and hypo